-transparent.png){kind=logo}
Young diabetes prone BB/Wor rats were treated for 4-7 weeks with low dose (1,000 units/week) or high dose (75,000 units/week) recombinant human interleukin-2 (IL-2) and observed through 150 days of age for the development of spontaneous diabetes mellitus. Comparing treated rats with controls, it was found that IL-2 did not affect the cumulative incidence of diabetes, the age at onset of the disease, or peripheral lymphocyte subset numbers. High dose IL-2 administered to diabetes resistant BB/Wor rats also failed to induce the disease.
Related Publications
D Burstein, and
E S Handler, and
J Schindler, and
J Seals, and
J P Mordes, and
A A Rossini
January 1989,
Autoimmunity,
D Burstein, and
E S Handler, and
J Schindler, and
J Seals, and
J P Mordes, and
A A Rossini
September 1994,
Medicine and science in sports and exercise,
D Burstein, and
E S Handler, and
J Schindler, and
J Seals, and
J P Mordes, and
A A Rossini
October 1990,
The American journal of pathology,
D Burstein, and
E S Handler, and
J Schindler, and
J Seals, and
J P Mordes, and
A A Rossini
January 1990,
Immunopharmacology,
D Burstein, and
E S Handler, and
J Schindler, and
J Seals, and
J P Mordes, and
A A Rossini
January 2000,
Annals of clinical and laboratory science,
D Burstein, and
E S Handler, and
J Schindler, and
J Seals, and
J P Mordes, and
A A Rossini
July 1993,
Diabetologia,
D Burstein, and
E S Handler, and
J Schindler, and
J Seals, and
J P Mordes, and
A A Rossini
April 1992,
Diabetes,
D Burstein, and
E S Handler, and
J Schindler, and
J Seals, and
J P Mordes, and
A A Rossini
August 1990,
Metabolism: clinical and experimental,
D Burstein, and
E S Handler, and
J Schindler, and
J Seals, and
J P Mordes, and
A A Rossini
November 1991,
Science (New York, N.Y.),
D Burstein, and
E S Handler, and
J Schindler, and
J Seals, and
J P Mordes, and
A A Rossini
January 1991,
International journal of immunopharmacology,
